

Recurrent Glioblastoma Multiforme Treatment Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/RF2287A58DBAEN.html>

Date: March 2022

Pages: 102

Price: US\$ 3,250.00 (Single User License)

ID: RF2287A58DBAEN

Abstracts

This report contains market size and forecasts of Recurrent Glioblastoma Multiforme Treatment in Global, including the following market information:

Global Recurrent Glioblastoma Multiforme Treatment Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Recurrent Glioblastoma Multiforme Treatment market was valued at 476.8 million in 2021 and is projected to reach US\$ 702.6 million by 2028, at a CAGR of 5.7% during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

AU-105 Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Recurrent Glioblastoma Multiforme Treatment include Boehringer Ingelheim GmbH, Boston Biomedical, Inc., Bristol-Myers Squibb Company, Cantex Pharmaceuticals, Inc., Cavion LLC, Celldex Therapeutics, Inc., Coherus BioSciences, Inc., Cortice Biosciences, Inc. and Eisai, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Recurrent Glioblastoma Multiforme Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends,

drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Recurrent Glioblastoma Multiforme Treatment Market, by Type, 2017-2022,
2023-2028 (\$ millions)

Global Recurrent Glioblastoma Multiforme Treatment Market Segment Percentages, by
Type, 2021 (%)

AU-105

Axitinib

AXL-1717

AZD-7451

Others

Global Recurrent Glioblastoma Multiforme Treatment Market, by Application,
2017-2022, 2023-2028 (\$ millions)

Global Recurrent Glioblastoma Multiforme Treatment Market Segment Percentages, by
Application, 2021 (%)

Hospital

Clinic

Others

Global Recurrent Glioblastoma Multiforme Treatment Market, By Region and Country,
2017-2022, 2023-2028 (\$ Millions)

Global Recurrent Glioblastoma Multiforme Treatment Market Segment Percentages, By
Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Recurrent Glioblastoma Multiforme Treatment revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Recurrent Glioblastoma Multiforme Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Cantex Pharmaceuticals, Inc.

Cavion LLC

Celldex Therapeutics, Inc.

Coherus BioSciences, Inc.

Cortice Biosciences, Inc.

Eisai

Eli Lilly and Company

EnGeneIC Ltd

ERC Belgium SA

GenSpera, Inc.

Genzyme Corporation

GW Pharmaceuticals Plc

ImmunoCellular Therapeutics, Ltd.

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Recurrent Glioblastoma Multiforme Treatment Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Recurrent Glioblastoma Multiforme Treatment Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT OVERALL MARKET SIZE

- 2.1 Global Recurrent Glioblastoma Multiforme Treatment Market Size: 2021 VS 2028
- 2.2 Global Recurrent Glioblastoma Multiforme Treatment Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Recurrent Glioblastoma Multiforme Treatment Players in Global Market
- 3.2 Top Global Recurrent Glioblastoma Multiforme Treatment Companies Ranked by Revenue
- 3.3 Global Recurrent Glioblastoma Multiforme Treatment Revenue by Companies
- 3.4 Top 3 and Top 5 Recurrent Glioblastoma Multiforme Treatment Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Recurrent Glioblastoma Multiforme Treatment Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Recurrent Glioblastoma Multiforme Treatment Players in Global Market
 - 3.6.1 List of Global Tier 1 Recurrent Glioblastoma Multiforme Treatment Companies

3.6.2 List of Global Tier 2 and Tier 3 Recurrent Glioblastoma Multiforme Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Recurrent Glioblastoma Multiforme Treatment Market Size Markets, 2021 & 2028

4.1.2 AU-105

4.1.3 Axitinib

4.1.4 AXL-1717

4.1.5 AZD-7451

4.1.6 Others

4.2 By Type - Global Recurrent Glioblastoma Multiforme Treatment Revenue & Forecasts

4.2.1 By Type - Global Recurrent Glioblastoma Multiforme Treatment Revenue, 2017-2022

4.2.2 By Type - Global Recurrent Glioblastoma Multiforme Treatment Revenue, 2023-2028

4.2.3 By Type - Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Recurrent Glioblastoma Multiforme Treatment Market Size, 2021 & 2028

5.1.2 Hospital

5.1.3 Clinic

5.1.4 Others

5.2 By Application - Global Recurrent Glioblastoma Multiforme Treatment Revenue & Forecasts

5.2.1 By Application - Global Recurrent Glioblastoma Multiforme Treatment Revenue, 2017-2022

5.2.2 By Application - Global Recurrent Glioblastoma Multiforme Treatment Revenue, 2023-2028

5.2.3 By Application - Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Recurrent Glioblastoma Multiforme Treatment Market Size, 2021 & 2028

6.2 By Region - Global Recurrent Glioblastoma Multiforme Treatment Revenue & Forecasts

6.2.1 By Region - Global Recurrent Glioblastoma Multiforme Treatment Revenue, 2017-2022

6.2.2 By Region - Global Recurrent Glioblastoma Multiforme Treatment Revenue, 2023-2028

6.2.3 By Region - Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Recurrent Glioblastoma Multiforme Treatment Revenue, 2017-2028

6.3.2 US Recurrent Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.3.3 Canada Recurrent Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.3.4 Mexico Recurrent Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Recurrent Glioblastoma Multiforme Treatment Revenue, 2017-2028

6.4.2 Germany Recurrent Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.4.3 France Recurrent Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.4.4 U.K. Recurrent Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.4.5 Italy Recurrent Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.4.6 Russia Recurrent Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.4.7 Nordic Countries Recurrent Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.4.8 Benelux Recurrent Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Recurrent Glioblastoma Multiforme Treatment Revenue, 2017-2028

6.5.2 China Recurrent Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.5.3 Japan Recurrent Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.5.4 South Korea Recurrent Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.5.5 Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.5.6 India Recurrent Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Recurrent Glioblastoma Multiforme Treatment Revenue, 2017-2028

6.6.2 Brazil Recurrent Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.6.3 Argentina Recurrent Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Revenue, 2017-2028

6.7.2 Turkey Recurrent Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.7.3 Israel Recurrent Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.7.4 Saudi Arabia Recurrent Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.7.5 UAE Recurrent Glioblastoma Multiforme Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Boehringer Ingelheim GmbH

7.1.1 Boehringer Ingelheim GmbH Corporate Summary

7.1.2 Boehringer Ingelheim GmbH Business Overview

7.1.3 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Major Product Offerings

7.1.4 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)

7.1.5 Boehringer Ingelheim GmbH Key News

7.2 Boston Biomedical, Inc.

7.2.1 Boston Biomedical, Inc. Corporate Summary

7.2.2 Boston Biomedical, Inc. Business Overview

7.2.3 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Major Product Offerings

7.2.4 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)

7.2.5 Boston Biomedical, Inc. Key News

7.3 Bristol-Myers Squibb Company

7.3.1 Bristol-Myers Squibb Company Corporate Summary

7.3.2 Bristol-Myers Squibb Company Business Overview

7.3.3 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Major Product Offerings

7.3.4 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)

7.3.5 Bristol-Myers Squibb Company Key News

7.4 Cantex Pharmaceuticals, Inc.

7.4.1 Cantex Pharmaceuticals, Inc. Corporate Summary

7.4.2 Cantex Pharmaceuticals, Inc. Business Overview

7.4.3 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Major Product Offerings

7.4.4 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)

7.4.5 Cantex Pharmaceuticals, Inc. Key News

7.5 Cavion LLC

7.5.1 Cavion LLC Corporate Summary

7.5.2 Cavion LLC Business Overview

7.5.3 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Major Product Offerings

7.5.4 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)

7.5.5 Cavion LLC Key News

7.6 Celldex Therapeutics, Inc.

7.6.1 Celldex Therapeutics, Inc. Corporate Summary

7.6.2 Celldex Therapeutics, Inc. Business Overview

7.6.3 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Major Product Offerings

7.6.4 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)

7.6.5 Celldex Therapeutics, Inc. Key News

7.7 Coherus BioSciences, Inc.

7.7.1 Coherus BioSciences, Inc. Corporate Summary

7.7.2 Coherus BioSciences, Inc. Business Overview

7.7.3 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Major Product Offerings

7.7.4 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)

7.7.5 Coherus BioSciences, Inc. Key News

7.8 Cortice Biosciences, Inc.

7.8.1 Cortice Biosciences, Inc. Corporate Summary

7.8.2 Cortice Biosciences, Inc. Business Overview

7.8.3 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Major Product Offerings

7.8.4 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue

in Global Market (2017-2022)

7.8.5 Cortice Biosciences, Inc. Key News

7.9 Eisai

7.9.1 Eisai Corporate Summary

7.9.2 Eisai Business Overview

7.9.3 Eisai Recurrent Glioblastoma Multiforme Treatment Major Product Offerings

7.9.4 Eisai Recurrent Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)

7.9.5 Eisai Key News

7.10 Eli Lilly and Company

7.10.1 Eli Lilly and Company Corporate Summary

7.10.2 Eli Lilly and Company Business Overview

7.10.3 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Major Product Offerings

7.10.4 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)

7.10.5 Eli Lilly and Company Key News

7.11 EnGeneIC Ltd

7.11.1 EnGeneIC Ltd Corporate Summary

7.11.2 EnGeneIC Ltd Business Overview

7.11.3 EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Major Product Offerings

7.11.4 EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)

7.11.5 EnGeneIC Ltd Key News

7.12 ERC Belgium SA

7.12.1 ERC Belgium SA Corporate Summary

7.12.2 ERC Belgium SA Business Overview

7.12.3 ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Major Product Offerings

7.12.4 ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)

7.12.5 ERC Belgium SA Key News

7.13 GenSpera, Inc.

7.13.1 GenSpera, Inc. Corporate Summary

7.13.2 GenSpera, Inc. Business Overview

7.13.3 GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Major Product Offerings

7.13.4 GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue in

Global Market (2017-2022)

7.13.5 GenSpera, Inc. Key News

7.14 Genzyme Corporation

7.14.1 Genzyme Corporation Corporate Summary

7.14.2 Genzyme Corporation Business Overview

7.14.3 Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Major Product Offerings

7.14.4 Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)

7.14.5 Genzyme Corporation Key News

7.15 GW Pharmaceuticals Plc

7.15.1 GW Pharmaceuticals Plc Corporate Summary

7.15.2 GW Pharmaceuticals Plc Business Overview

7.15.3 GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Major Product Offerings

7.15.4 GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)

7.15.5 GW Pharmaceuticals Plc Key News

7.16 ImmunoCellular Therapeutics, Ltd.

7.16.1 ImmunoCellular Therapeutics, Ltd. Corporate Summary

7.16.2 ImmunoCellular Therapeutics, Ltd. Business Overview

7.16.3 ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Major Product Offerings

7.16.4 ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)

7.16.5 ImmunoCellular Therapeutics, Ltd. Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Recurrent Glioblastoma Multiforme Treatment Market Opportunities & Trends in Global Market

Table 2. Recurrent Glioblastoma Multiforme Treatment Market Drivers in Global Market

Table 3. Recurrent Glioblastoma Multiforme Treatment Market Restraints in Global Market

Table 4. Key Players of Recurrent Glioblastoma Multiforme Treatment in Global Market

Table 5. Top Recurrent Glioblastoma Multiforme Treatment Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Recurrent Glioblastoma Multiforme Treatment Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Recurrent Glioblastoma Multiforme Treatment Revenue Share by Companies, 2017-2022

Table 8. Global Companies Recurrent Glioblastoma Multiforme Treatment Product Type

Table 9. List of Global Tier 1 Recurrent Glioblastoma Multiforme Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Recurrent Glioblastoma Multiforme Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Recurrent Glioblastoma Multiforme Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Recurrent Glioblastoma Multiforme Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Recurrent Glioblastoma Multiforme Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Recurrent Glioblastoma Multiforme Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Recurrent Glioblastoma Multiforme Treatment Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Recurrent Glioblastoma Multiforme Treatment Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2023-2028

Table 30. Boehringer Ingelheim GmbH Corporate Summary

Table 31. Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Product Offerings

Table 32. Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Revenue (US\$, Mn), (2017-2022)

Table 33. Boston Biomedical, Inc. Corporate Summary

Table 34. Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Product Offerings

Table 35. Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue (US\$, Mn), (2017-2022)

Table 36. Bristol-Myers Squibb Company Corporate Summary

Table 37. Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Product Offerings

Table 38. Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Revenue (US\$, Mn), (2017-2022)

Table 39. Cantex Pharmaceuticals, Inc. Corporate Summary

Table 40. Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Product Offerings

Table 41. Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment

Revenue (US\$, Mn), (2017-2022)

Table 42. Cavion LLC Corporate Summary

Table 43. Cavion LLC Recurrent Glioblastoma Multiforme Treatment Product Offerings

Table 44. Cavion LLC Recurrent Glioblastoma Multiforme Treatment Revenue (US\$, Mn), (2017-2022)

Table 45. Celldex Therapeutics, Inc. Corporate Summary

Table 46. Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Product Offerings

Table 47. Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue (US\$, Mn), (2017-2022)

Table 48. Coherus BioSciences, Inc. Corporate Summary

Table 49. Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Product Offerings

Table 50. Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue (US\$, Mn), (2017-2022)

Table 51. Cortice Biosciences, Inc. Corporate Summary

Table 52. Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Product Offerings

Table 53. Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue (US\$, Mn), (2017-2022)

Table 54. Eisai Corporate Summary

Table 55. Eisai Recurrent Glioblastoma Multiforme Treatment Product Offerings

Table 56. Eisai Recurrent Glioblastoma Multiforme Treatment Revenue (US\$, Mn), (2017-2022)

Table 57. Eli Lilly and Company Corporate Summary

Table 58. Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Product Offerings

Table 59. Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Revenue (US\$, Mn), (2017-2022)

Table 60. EnGeneIC Ltd Corporate Summary

Table 61. EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Product Offerings

Table 62. EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Revenue (US\$, Mn), (2017-2022)

Table 63. ERC Belgium SA Corporate Summary

Table 64. ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Product Offerings

Table 65. ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Revenue (US\$, Mn), (2017-2022)

Table 66. GenSpera, Inc. Corporate Summary

Table 67. GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Product Offerings

Table 68. GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue (US\$, Mn), (2017-2022)

Table 69. Genzyme Corporation Corporate Summary

Table 70. Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Product Offerings

Table 71. Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Revenue (US\$, Mn), (2017-2022)

Table 72. GW Pharmaceuticals Plc Corporate Summary

Table 73. GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Product Offerings

Table 74. GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Revenue (US\$, Mn), (2017-2022)

Table 75. ImmunoCellular Therapeutics, Ltd. Corporate Summary

Table 76. ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Product Offerings

Table 77. ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Recurrent Glioblastoma Multiforme Treatment Segment by Type in 2021
- Figure 2. Recurrent Glioblastoma Multiforme Treatment Segment by Application in 2021
- Figure 3. Global Recurrent Glioblastoma Multiforme Treatment Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Recurrent Glioblastoma Multiforme Treatment Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Recurrent Glioblastoma Multiforme Treatment Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Recurrent Glioblastoma Multiforme Treatment Revenue in 2021
- Figure 8. By Type - Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Recurrent Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028
- Figure 12. US Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Recurrent Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028
- Figure 16. Germany Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028

2017-2028

Figure 21. Nordic Countries Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Recurrent Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028

Figure 24. China Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028

Figure 28. India Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Recurrent Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028

Figure 30. Brazil Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028

Figure 33. Turkey Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Recurrent Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028

Figure 37. Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Cavion LLC Recurrent Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Eisai Recurrent Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 49. GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 50. Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 51. GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 52. ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Recurrent Glioblastoma Multiforme Treatment Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/RF2287A58DBAEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RF2287A58DBAEN.html>